A deep tech startup developing a personalized shoe manufacturing platform that integrates 3D scanning, automated design algorithms, and 3D printing. DIFF.3D—which automatically designs optimal footwear from 3D foot scan data and delivers shoes on demand—is set to launch in June 2026. The platform addresses Japan's approximately 25 million "shoe refugees" who struggle to find well-fitting off-the-shelf footwear, while also pursuing a B2B model as an industry infrastructure for other shoe brands.
「足が喜ぶ、あしたをつくる。」をビジョンに掲げる株式会社DIFF.（本社：大阪市中央区、代表：清水雄一）は、池田泉州キャピタル株式会社とライトアップベンチャーズから総額4500万円の資金調達を実施。既存の「...
[画像1: https://prtimes.jp/i/111515/12/resize/d111515-12-7403e80582e8fd10c2a0-0.png ] ビジョン「足が喜ぶ、あしたをつくる。」を掲げ、片方ずつシューズを買えるサービス『DIFF.』の運営を行う株式会社DIFF...
[画像1: https://prtimes.jp/i/111515/11/resize/d111515-11-294809b63e02be455a94-0.jpg ] ビジョン「足が喜ぶ、あしたをつくる。」を掲げ、片方ずつシューズを買えるサービス『DIFF.』の運営を行う株式会社DIFF...
[画像1: https://prtimes.jp/i/111515/10/resize/d111515-10-a9cabd93017d312f15a3-0.jpg ] ビジョン「足が喜ぶ、あしたをつくる。」を掲げ、片方ずつシューズを買えるサービス『DIFF.』の運営を行う株式会社DIFF...
■「NEXT100」とは 「NEXT100」とは、「多彩な新・起業家たち100人」にフォーカスした企画。地球規模から社会、地域まで、さまざまな課題に対してアントレプレナーシップをもち、「自分たちのあり方」と「新手法」...
4メーカー・15種類のサッカースパイクの左右別サイズ販売を開始 靴擦れの症状を抱える人の1割超が「原因は足のサイズの左右差」と回答 元 世代別サッカー日本代表選手も利用し、左右別サイズ購入の必要性を実感...
[画像: https://prtimes.jp/i/111515/7/resize/d111515-7-52e29953aed298056291-0.png ] ■事業概要 主に足のサイズに左右差のある方に向けて、シューズ片足購買サービスを提供しています。シューズメーカーと連...
[画像1: https://prtimes.jp/i/111515/6/resize/d111515-6-9fcd217c95e5dd382922-0.jpg ] 当社販売サイトにて新しい商品「WAVE RIDER27」の取り扱いを9月21日に開始しました。以前から取り扱いがあった「WAVE RI...
[画像1: https://prtimes.jp/i/111515/5/resize/d111515-5-0669c7c4598e5f9cf506-0.png ] ■調査概要 調査概要：サイズの合わない靴を履くことによる健康への影響調査 調査方法：IDEATECHが提供するリサーチPR「...
[画像1: https://prtimes.jp/i/111515/4/resize/d111515-4-82ff7c73fc42755cb48c-0.jpg ] ■シューズ片足購買サービス『DIFF.』とは 左右で同じサイズの靴を買うことが現代の当たり前です。一方で、5人に1人は足...
A startup developing proprietary technology that utilizes fish-derived gut bacteria to enhance aquaculture fish growth and strengthen immunity. Centered on aquaculture support through bacterial cocktails, it also tackles land-based aquaculture and branded fish production.
Elcyo develops innovative autofocal glasses that automatically adjust focus with proprietary lens technology. Leveraging Fresnel Liquid Crystal Lens Technology, Elcyo has made it possible to create glasses that maintain focus at any distance, addressing a wide range of vision challenges across healthcare, entertainment, and beyond.
Our company engages in the research and development, manufacturing, and sales of diagnostic test kits, primarily focused on in vitro diagnostic (IVD) products. In the field of infectious diseases, we provide rapid diagnostic kits for tropical infectious diseases such as dengue fever. In the pre-symptomatic healthcare field, we offer testing solutions—including genetic testing and microbiological testing—for individual and corporate sales, as well as for medical and research institutions. In addition, we collaborate not only within Japan but also with overseas bases and partners, including those in Thailand, and have established a product development and supply system that complies with regulatory requirements in each country.
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
